Sionna Therapeutics, Inc. (SION)
NASDAQ: SION · Real-Time Price · USD
7.18
+0.14 (1.99%)
Sep 17, 2026, 4:00 PM EDT - Market closed
Sionna Therapeutics Employees
Sionna Therapeutics had 59 employees as of December 31, 2025. The number of employees increased by 18 or 43.90% compared to the previous year.
Employees
59
Change
18
Growth
43.90%
Revenue / Employee
n/a
Profits / Employee
-$1,650,559
Market Cap
324.63M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 59 | 18 | 43.90% |
| Mar 31, 2025 | 48 | 20 | 71.43% |
| Dec 31, 2024 | 41 | 13 | 46.43% |
| Dec 31, 2023 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| EyePoint | 214 |
| Ocugen | 116 |
| SAB Biotherapeutics | 86 |
| Agenus | 81 |
| Century Therapeutics | 78 |
| InflaRx | 65 |
SION News
- 2 days ago - Sionna Therapeutics price target raised to $6 from $5 at Wedbush - TheFly
- 3 days ago - Sionna Therapeutics Transcript: Study update - Transcripts
- 3 days ago - Sionna Therapeutics Press release: Study update - Filings
- 3 days ago - Sionna Therapeutics Slides: Study update - Filings
- 3 days ago - Sionna Therapeutics to advance SION-451 + SION-2222 into AscenSION CF POC trial - TheFly
- 3 days ago - Sionna Therapeutics to reduce workforce by 46% - TheFly
- 3 days ago - Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial - GlobeNewsWire
- 4 weeks ago - Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics - PRNewsWire